Quantification of antimalarial bisthiazolium compounds and their neutral bioprecursors in plasma by liquid chromatography-electrospray mass spectrometry

Clinical Chemistry

Volumn 51, Issue 3, 2005, Pages 593-602

  Nicolas, Olivier ^a   Farenc, Christine ^b   Calas, Michèle ^b   Vial, Henri J ^b   Bressolle, Françoise ^a  

^a UNIV MONTPELLIER   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,12 BIS[4 METHYL 5 (2 HYDROXYETHYL) THIAZOL 3 IUM 3 YL]DODECANE DIBROMIDE; 1,12 BIS[4 METHYL 5 (2 METHOXYETHYL) THIAZOL 3 IUM 3 YL]DODECANE DIBROMIDE; ACETONITRILE; ANTIMALARIAL AGENT; BISTHIAZOLIUM; N,N DIFORMYL N,N DI[1 METHYL 2 S THIOBENZOYL 4 METHOXYBUT 1 ENYL] 1,12 DIAMINODODECANE; PRODRUG; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; DRUG ANALYSIS; DRUG BINDING; DRUG BLOOD LEVEL; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; NONHUMAN; PLASMA PROTEIN BINDING; RAT; SOLID PHASE EXTRACTION;

ANIMALS; ANTIMALARIALS; BLOOD PROTEINS; CHROMATOGRAPHY, LIQUID; DIAMINES; HUMANS; PLASMA; PRODRUGS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THIAZOLES;

EID: 14544291958     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.042580     Document Type: Article

References (21)

1. Greenwood B, Mutabingwa T. Malaria in 2002. Nature 2002;415:670-2.
2. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002;2:209-18.
3. Ancelin ML, Calas M, Bompart J, Cordina G, Martin D, Ben Bari M, et al. Antimalarial activity of 77 phospholipid polar head analogs: close correlation between inhibition of phospholipid metabolism and in vitro Plasmodium falciparum growth. Blood 1998;91:1426-37.
4. Ancelin ML, Calas M, Vidal-Sailhan V, Herbute S, Ringwald P, Vial HJ. Potent inhibitors of Plasmodium phospholipid metabolism with a broad spectrum of in vitro antimalarial activities. Antimicrob Agents Chemother 2003;47:2590-7.
5. Ancelin ML, Calas M, Bonhoure A, Herbute S, Vial HJ. In vivo antimalarial activities of mono- and bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolism. Antimicrob Agents Chemother 2003;47:2598-605.
6. Calas M, Ancelin ML, Cordina G, Portefaix P, Piquet G, Vidal-Sailhan V, et al. Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts. J Med Chem 2000;43:505-16.
7. Calas M, Cordina G, Bompart J, Ben Bari M, Jei T, Ancelin ML, et al. Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism. Structure-activity relationship analysis. J Med Chem 1997;40:3557-66.
8. Vial HJ, Ancelin ML, Philippot JR, Thuet MJ. Biosynthesis and dynamics of lipids in plasmodium-infected mature mammalian erythrocytes. Blood Cells 1990;16:531-55.
9. Vial HJ, Calas M. Inhibitors of phospholipid metabolism. In: Rosenthal PJ, ed. Antimalarial chemotherapy: mechanism of action, resistance, and new directions in drug discovery. Totowa, NJ: Humana Press, 2000:347-65.
10. Wengelnik K, Vidal V, Ancelin ML, Cathiard AM, Morgat JL, Kocken CH, et al. A class of potent antimalarials and their specific accumulation in infected erythrocytes. Science 2002;295:1311-4.
11. Vial H, Wein S, Farenc C, Kocken C, Nicolas O, Ancelin ML, et al. Precursors of bisthiazolium are potent antimalarials. Proc Natl Acad Sci U S A, 2004;101:15458-63.
12. US Food and Drug Administration. Guidance for industry. Bioanalytical method validation. May 2001. http://www.fda.gov/cder/guidance/index.htm (accessed May 2004).
13. United States Pharmacopoeia XXXIII. Rockville, MD: The United States Pharmacopoeia Convention, 2003:2439.
14. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci 1992;81:309-12.
15. Bressolle F, Bromet-Petit M, Audran M. Validation of liquid chromatographic and gas chromatographic methods. Application to pharmacokinetics. J Chromatogr B 1996;686:3-10.
16. Vial H, Calas M, Bourguignon JJ, Ancelin ML, Vidal V, Rubi E, inventors. Précurseurs de sels de bis-ammonium quaternaire et leurs applications comme prodrogues ayant une activité antiparasitaire. World Patent 99 09471 applied for by CNRS, 21 July 1999; WO 0105742 A1, published January 25, 2001.
17. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal Chem 1998;70:882-9.
18. Barre J, Chamouard JM, Houin G, Tillement, JP. Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem 1985;31:60-4.
19. National Institutes of Health. Principles of laboratory animal care, revised. NIH publication 85-23. Bethesda, MD: NIH, 1985.
20. Farenc C, Fabreguette JR, Bressolle F. Pk-fit: a pharmacokinetic/ pharmacodynamic and statistical data analysis software. Comput Biomed Res 2000;33:315-30.
21. Research and Development for Population Pharmacokinetics (RDPP). Pk-fit computer program, Ver. 2.1. Montpellier, France: RDPP, 1999.